Tom Waddell - Publications, H-index & Citations

Back

Tom Waddell

The Christie NHS Foundation Trust

13H-index

39Paper Count

1.6KCitation Count

Published Papers 15

Publication Date

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

British Journal of Cancer

IF6.8

2026-04-21

OAAI

Anderley Gordon; Amina Tran; Caroline Fong; Susan Cromarty; Katarzyna Piadel; Oleg Zhitkov; Becky Leamon; Catherine Cafferkey; Michael Davidson; Prantik Das; Russell Petty; Tom Roques; Madeleine Hewish; Carys Morgan; Tom Waddell; Suzanne Darby; Alexander Bradshaw; Sheela Rao; Naureen Starling; Ian Chau; David Cunningham

Save

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

Nature Medicine

IF50

2025-08-01

OAAI

Brian I. Rini; Elizabeth R. Plimack; Viktor Stus; Rustem Gafanov; Tom Waddell; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Sergio Jobim de Azevedo; Delphine Borchiellini; Raymond S. McDermott; Jens Bedke; Satoshi Tamada; Sterling Wu; Julia Markensohn; Yiwei Zhang; Andrey Loboda; Amir Vajdi; Rodolfo F. Perini; Joseph Burgents; Thomas Powles

Save

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis (vol 26, pg 1639, 2024)

CURRENT ONCOLOGY REPORTS

IF5

2025-05-09

OAAI

Frazer, Ricky; Arranz, Jose angel; Estevez, Sergio Vazquez; Parikh, Omi; Krabbe, Laura-Maria; Vasudev, Naveen S.; Doehn, Christian; Marschner, Norbert; Waddell, Tom; Ince, Will; Goebell, Peter J.

Save

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Annals of Oncology

IF65.4

2025-04-01

OAAI

L. Bergmann; L. Albiges; M. Ahrens; M. Gross-Goupil; E. Boleti; G. Gravis; A. Fléchon; M.-O. Grimm; J. Bedke; P. Barthélémy; D. Castellano; B. Mellado; P. Ivanyi; S. Rottey; A. Flörcken; C. Suarez; P. Maroto; V. Grünwald; S.F. Oosting; J. Kopecky; S. Zschäbitz; M. Boegemann; T. Buchler; G. Niegisch; P.J. Goebell; T. Waddell; F. Joly; F. Priou; M. Retz; S. Siemer; U. Zimmermann; D. Deckbar; I. Burkholder; A. Hartmann; J.B. Haanen

Save

Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population

FUTURE ONCOLOGY

IF2.6

2024-10-09

OAAI

Waddell, Tom; Pillai, Manon; Armitage, Kate; Graham, Donna M.; Moran, Michael; Dilleen, Maria; Holmes, Sinead; Sleszynska-Dopiera, Ewa; Hawkins, Robert

Save

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis

HEALTH TECHNOLOGY ASSESSMENT

IF4

2024-08-01

OAAI

Fleeman, Nigel; Houten, Rachel; Nevitt, Sarah; Mahon, James; Beale, Sophie; Boland, Angela; Greenhalgh, Janette; Edwards, Katherine; Maden, Michelle; Bhattacharyya, Devarshi; Chaplin, Marty; McEntee, Joanne; Chow, Shien; Waddell, Tom

Save

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study[Eur Urol 84(5) (2023) 449-454]

EUROPEAN UROLOGY

IF25.2

2023-12-01

OAAI

Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; McDermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Molife, L. Rhoda; Li, Chenxiang; Perini, Rodolfo; Bedke, Jens; Rini, Brian I.

Save

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

EUROPEAN UROLOGY

IF25.2

2023-11-01

PREAI

Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; Mcdermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Li, Chenxiang; Perini, Rodolfo; Molife, L. Rhoda; Bedke, Jens; Rini, Brian I.

Save

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study ( vol 84 , pg , 449 , 2023)

EUROPEAN UROLOGY

IF25.2

2023-11-01

OAAI

Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Poulioti, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; McDermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Li, Chenxiang; Perini, Rodolfo; Molife, L. Rhoda; Bedke, Jens; Riniu, Brian I.

Save

Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis

TARGETED ONCOLOGY

IF4

2023-06-07

PREAI

Heseltine, Jonathan; Allison, Jennifer; Wong, Sam; Prasad, Kellati; Oong, Zhu-Chuen; Wong, Helen; Law, Andrea; Charnley, Natalie; Parikh, Omi; Waddell, Tom; Chow, Shien

Save

Non-invasive treatment of ischemia/reperfusion injury: Effective transmission of therapeutic near-infrared light into the human brain through soft skin-conforming silicone waveguides

BIOENGINEERING & TRANSLATIONAL MEDICINE

IF5.7

2023-02-07

OAAI

Morse, Paul T.; Tuck, Samuel; Kerns, Mike; Goebel, Dennis J.; Wan, Junmei M.; Waddell, Tom; Wider, Joseph M.; Huttemann, Charlotte L.; Malek, Moh H.; Lee, Icksoo C.; Sanderson, Thomas H.; Huttemann, Maik

Save

EUROPEAN UROLOGY

IF25.2

2022-10-01

PREAI

Bedke, Jens; Rini, Brian, I; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dimitry; Pouliot, Frederic; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J.; Borchiellini, Delphine; McDermott, Raymond S.; Tamada, Satoshi; Nguyen, Allison Martin; Wan, Shuyan; Perini, Rodolfo F.; Molife, L. Rhoda; Atkins, Michael B.; Powles, Thomas

Save

Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Vasudev, N. S.; Ainsworth, G.; Brown, S.; Pickering, L.; Waddell, T. S.; Fife, K.; Griffiths, R.; Sharma, A.; Katona, E.; Howard, H.; Velikova, G.; Maraveyas, A.; Brown, J. E.; Venugopal, B.; Patel, P.; Jain, A.; Symeonides, S.; Nathan, P. D.; Collinson, F.; Powles, T. B.

Save

Subsequent therapy following pembrolizumab plus axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Gafanov, R.; Powles, T. B.; Bedke, J.; Stus, V.; Waddell, T. S.; Nosov, D.; Pouliot, F.; Soulieres, D.; Melichar, B.; Azevedo, S.; McDermott, R. S.; Vynnychenko, I. O.; Borchiellini, D.; Markus, M.; Bondarenko, I.; Lin, J.; Burgents, J.; Molife, L. R.; Plimack, E. R.; Rini, B.

Save

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

BMC CANCER

IF3.4

2019-11-14

OAAI

Buckley, Hannah L.; Collinson, Fiona J.; Ainsworth, Gemma; Poad, Heather; Flanagan, Louise; Katona, Eszter; Howard, Helen C.; Murden, Geraldine; Banks, Rosamonde E.; Brown, Joanne; Velikova, Galina; Waddell, Tom; Fife, Kate; Nathan, Paul D.; Larkin, James; Powles, Thomas; Brown, Sarah R.; Vasudev, Naveen S.

Save

Research Directions